"Continuous improvement of our quality and compliance standards across all our manufacturing sites is a key focus area for the company and we are committed to working with the USFDA
to manufacture and supply products of the highest quality from all our manufacturing sites," he added.
On Wednesday, the company announced that it received tentative approval for its Arformoterol Tartrate Inhalation Solution from the US drug regulator. The solution is indicated for the long-term maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD).
Following the development, Lupin
shares gained 1.62% to Rs 868.10 before falling to Rs 823.